Effect of soluble Fas ligand (sFasL) on vascular endothelial growth factor (VEGF)production by synovial fibroblasts

<p><b>Copyright information:</b></p><p>Taken from "Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis"</p><p>http://arthritis-research.com/content/9/2/R42</p><p>Arthritis Research & Therapy 2007;9(2):R42-R42.</p><p>Published online 26 Apr 2007</p><p>PMCID:PMC1906820.</p><p></p> Fibroblast-like synoviocytes (FLSs) were cultured in triplicate for 24 hours with medium alone and transforming growth factor (TGF)-β (10 ng/ml) in the presence of various concentrations of sFasL (10 to 100 ng/ml). The amount of VEGFin the culture supernatants was determined by ELISA. Data are the mean ± standard deviation (SD) of three independent experiments in triplicate. *< 0.05; < 0.01 versus the cells stimulated with medium alone or TGF-β in the absence of sFasL. The rheumatoid arthritis FLSs (RAFLS; = 7) or osteoarthritis FLSs (OAFLS; = 5) were treated with increasing concentrations of sFasL (1 to 100 ng/ml) in the absence or presence of 1% FCS for 24 hours. The viability of FLS was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data are expressed as the mean ± SD. *< 0.01 versus OAFLS